PDF(Pubmed)
Abstract：
Zanubrutinib, a next-generation non-covalent Bruton\'s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib. Grade 4 dermatological toxicities are rare, which present as severe rash and skin infection. Herein, we retrospectively reported the grade 4 dermatological toxicities of zanubrutinib in three consecutive patients. They were treated with zanubrutinib 160 mg twice daily orally. One patient was diagnosed with Primary Breast Diffuse Large B-cell Lymphoma(PB-DLBCL) and two patients were diagnosed with Chronic Lymphocytic Leukemia(CLL). Within one month after zanubrutinib treatment, all three patients developed grade 4 dermatological toxicities, including bruising, maculopapular rash, petechiae, ecchymosis, hemorrhagic blister, acne-Like rash, papulopustular rash, and skin infections. Zanubrutinib was discontinued in two patients due to unacceptable dermatological toxicities. Safety data from pre-licensing clinical trials showed that zanubrutinib-related side effects were frequent but well tolerated. To date, no severe dermatological toxicities were reported. The majority of patients can be relieved with symptomatic treatment, but a very small percentage of patients may face discontinuation of the drug.
摘要：
扎努布替尼,下一代非共价布鲁顿酪氨酸激酶（BTK）抑制剂，在治疗B细胞恶性肿瘤方面显示出巨大的疗效。一些患者在扎努布替尼治疗后可能会出现一系列副作用。4级皮肤病毒性很少见，表现为严重的皮疹和皮肤感染。在这里，我们回顾性报道了3例连续患者的zanubrutinib4级皮肤病毒性.他们用扎努布替尼160mg每天两次口服治疗。一名患者被诊断为原发性乳腺弥漫性大B细胞淋巴瘤（PB-DLBCL），两名患者被诊断为慢性淋巴细胞白血病（CLL）。扎努布替尼治疗后一个月内，所有三名患者都出现了4级皮肤病毒性，包括瘀伤,斑丘疹,瘀斑,瘀斑,出血性水疱,痤疮样皮疹,丘疹脓疱皮疹,和皮肤感染。由于不可接受的皮肤病毒性，两名患者停用了Zanubrutinib。来自许可前临床试验的安全性数据表明，扎努布替尼相关副作用频繁，但耐受性良好。迄今为止,没有严重的皮肤病毒性报告.多数患者经对症治疗可以缓解,但是只有一小部分患者可能面临停药。
